Ming-Kuei Jang is the founder of APRINOIA Therapeutics. APRINOIA Therapeutics has raised $11M in total funding. Latest round: Series B.
Ming-Kuei Jang is the founder and CEO of APRINOIA Therapeutics, a clinical-stage neuroscience biotech company founded in 2015. The company focuses on developing precision diagnostics and targeted therapeutics for neurodegenerative diseases like Alzheimer's and Progressive Supranuclear Palsy. APRINOIA Therapeutics has raised capital through multiple venture rounds, including a $11.1 million Series B.
Full founder directory · Investor directory · Company funding database · Fundraising library